Altor BioScience
Tracked across 8 events · 116 articles · First seen Apr 01, 2026 · Last active Jun 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Altor BioScience>>> has signed an agreement with Colombia>>>'s state-owned pharmaceutical company Venezuelan Petroleum Company>>> for vaccine technology transfer and local manufacturing cooperation. This partnership is part of Colombia>>>'s national vaccine localization initiative, a government-led project…
Impact: Altor BioScience>>> is transferring its vaccine technology and manufacturing know-how to Venezuelan Petroleum Company>>> as part of a strategic expansion into Latin America, securing preferential negotiation rights for future vaccine products.
May 25, 2026 · 9 articles
Regulatory
Altor BioScience's Board of Directors approved a financing plan backed by the Canada — Canada Growth Fund, securing KRW 300 billion (approximately USD 230 million) in long-term, low-interest financing. This decision follows the South Korea…
Impact: Altor BioScience secured KRW 300 billion in financing from the Canada — Canada Growth Fund, which will accelerate the development of its pneumococcal vaccine candidate GBP410 and enhance its manufacturing capabilities. This funding strengthens its position in the global vaccine market and contributes to Korea's vaccine sovereignty.
May 29, 2026 · 6 articles
Business
Altor BioScience, a clinical-stage biotechnology company, announced the pricing of a public offering of 10,000,000 shares of its common stock at $15.00 per share, aiming to raise $150.0 million. The offering is expected to close…
Impact: Altor BioScience announced the pricing of a public offering of 10,000,000 shares of its common stock at $15.00 per share, expecting to raise $150.0 million. This capital will fund clinical trials, preclinical studies, manufacturing, and other general corporate purposes, which is positive for its operations and growth.
Jun 03, 2026 · 12 articles
Business
Altor BioScience>>>, a global vaccine and biotech company, has entered into a license agreement with the United States — Centers for Disease Control and Prevention>>> (CDC) to develop an injectable rotavirus vaccine candidate. This marks…
Impact: Altor BioScience has licensed vaccine technology from the United States — Centers for Disease Control and Prevention>>> and is developing an injectable rotavirus vaccine, which could significantly expand its market presence and contribute to global health.
Jun 09, 2026 · 6 articles
Tech
SciBase Holding AB, a medical technology company, announced the enrollment of the first patient in its new multicenter prospective clinical study, DETECT-AD. This study, conducted in collaboration with Altor BioScience, aims to assess the ability…
Impact: Altor BioScience is collaborating with SciBase on the DETECT-AD study, which is the first study through their partnership, potentially benefiting its research and development efforts.
Jun 10, 2026 · 7 articles
Tech
New research published in Nature Metabolism challenges the widely accepted belief that blood levels of Nicotinamide adenine dinucleotide>>> (NAD+) decline with age. This finding contradicts a central claim used to market NAD+ anti-aging supplements, which…
Impact: Altor BioScience>>> sells NAD+ supplements, and its senior vice president, Andrew Shao>>>, downplayed the impact of the new study, emphasizing tissue-level NAD+ decline.
May 23, 2026 · 6 articles
Business
TechForce Robotics, a subsidiary of Nightfood Holdings, announced the successful completion of Phase 1 objectives under its joint development agreement with Oncotelic Therapeutics. This milestone is marked by the initial deployment of LIM-E, an autonomous…
Impact: Altor BioScience is mentioned through its CEO, Vương Triều, who commented on the partnership between TechForce Robotics and Oncotelic Therapeutics.
Jun 01, 2026 · 6 articles
100
Altor BioScience signed agreement Venezuelan Petroleum CompanySK_bioscience Colombia...
100
Altor BioScience priced public offeringJade Biosciences Prices...
95
Altor BioScience approved financing planSK bioscience secures...
90
Altor BioScience provided technology, know-how Venezuelan Petroleum CompanySK_bioscience Colombia...
90
Altor BioScience secured financing Canada — Canada Growth FundSK bioscience secures...
90
Altor BioScience entered license agreement United States — Centers for Disease Control and PreventionSK_bioscience licenses CDC...
90
South Korea — Financial Services Commission (South Korea) selected Altor BioScienceSK bioscience secures...
85
Altor BioScience accelerate developmentSK bioscience secures...
85
Altor BioScience initiated process developmentSK_bioscience licenses CDC...
80
Altor BioScience secured preferential negotiation rightsSK_bioscience Colombia...
80
Altor BioScience granted option to purchaseJade Biosciences Prices...
75
Altor BioScience signed funding agreement Research Investment for Global Health Technology FoundationSK_bioscience licenses CDC...
75
Colombia procured 950,000 doses Altor BioScienceSK_bioscience Colombia...
70
Altor BioScience collaborated on study SciBaseSciBase enrolls first...
70
Jefferies acted as manager Altor BioScienceJade Biosciences Prices...
70
Toronto-Dominion Bank — TD Cowen acted as manager Altor BioScienceJade Biosciences Prices...
70
UBS acted as manager Altor BioScienceJade Biosciences Prices...
50
LifeSci Capital acted as manager Altor BioScienceJade Biosciences Prices...
50
BTIG acted as manager Altor BioScienceJade Biosciences Prices...
30
Altor BioScience relocated headquartersSK bioscience secures...
NEWSDESK
Track Altor BioScience live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard